MCA
AZN icon

Maryland Capital Advisors’s AstraZeneca AZN Stock Holding History

Maryland Capital Advisors’s Portfolio AZN Stock Details AZN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$7.21K Buy
+38
New +$7.15K ﹤0.01% 207
2025
Q4 		$7.08K Sell
39
-3
-7% -$526 ﹤0.01% 212
2025
Q3 		$6.45K Hold
42
– – ﹤0.01% 200
2025
Q2 		$5.87K Hold
42
– – ﹤0.01% 216
2025
Q1 		$6.17K Hold
42
– – ﹤0.01% 180
2024
Q4 		$5.5K Hold
42
– – ﹤0.01% 203
2024
Q3 		$6.54K Hold
42
– – ﹤0.01% 193
2024
Q2 		$6.55K Hold
42
– – ﹤0.01% 190
2024
Q1 		$5.69K Sell
42
-58
-58% -$7.68K ﹤0.01% 177
2023
Q4 		$13.5K Hold
100
– – 0.01% 162
2023
Q3 		$13.5K Hold
100
– – 0.01% 157
2023
Q2 		$14.3K Hold
100
– – 0.01% 164
2023
Q1 		$13.9K Hold
100
– – 0.01% 162
2022
Q4 		$13.6K Hold
100
– – 0.01% 164
2022
Q3 		$11K Hold
100
– – 0.01% 159
2022
Q2 		$13K Buy
+100
New +$13.1K 0.01% 152

Other funds holding AZN

EPGL
Evelyn Partners Group Ltd London $46.9B AUM
Deutsche Bank
Deutsche Bank Frankfurt Am Main Ge, Germany $344B AUM 42.99% 1-Year Est. Return
Fisher Asset Management
Fisher Asset Management Camas, Washington $336B AUM 34.66% 1-Year Est. Return
RG
Rathbones Group Liverpool, United Kingdom $27.1B AUM 20.2% 1-Year Est. Return
Bank of New York Mellon
Bank of New York Mellon New York $609B AUM 40.19% 1-Year Est. Return
SAM
SEB Asset Management Stockholm $26.6B AUM
CDDEC
Caisse Des Depots Et Consignations Paris, France $5.91B AUM 35.65% 1-Year Est. Return
Citigroup
Citigroup New York $303B AUM 53.02% 1-Year Est. Return
MGP
M&G plc London, United Kingdom $20.1B AUM 16.62% 1-Year Est. Return
DekaBank Deutsche Girozentrale
DekaBank Deutsche Girozentrale Frankfurt, Germany $59.2B AUM 26.02% 1-Year Est. Return

Maryland Capital Advisors's AZN Position: Q2 2026 in Review

Maryland Capital Advisors opened a new position in AstraZeneca (AZN) in Q2 2026: 38 shares worth $7.21K. The stake represents ﹤0.01% of the portfolio and ranks #207 among its holdings. This is a return to the name: Maryland Capital Advisors previously reported a position in AZN as recently as Q4 2025.

Maryland Capital Advisors first reported a position in AZN in Q2 2022 and has held it in 16 quarters since. The position peaked at $14.3K in Q2 2023. 906 funds tracked by Wall St. Rank hold AZN as of Q2 2026.

  • Maryland Capital Advisors held 38 shares of AstraZeneca worth $7.21K as of Q2 2026.
  • AstraZeneca was a new Maryland Capital Advisors position in Q2 2026.
  • AstraZeneca made up ﹤0.01% of Maryland Capital Advisors's portfolio in Q2 2026, its #207 holding.
  • Maryland Capital Advisors first reported a position in AstraZeneca in Q2 2022 and has held it in 16 quarters since.
  • Maryland Capital Advisors's AstraZeneca position peaked at $14.3K in Q2 2023.
  • 906 funds tracked by Wall St. Rank held AstraZeneca as of Q2 2026.

Based on Maryland Capital Advisors's 13F filing for Q2 2026, filed 17 Jul 2026.